LPC
RIGL icon

Loeb Partners Corp’s Rigel Pharmaceuticals RIGL Stock Holding History

Loeb Partners Corp’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200
Closed -$5K – 106
2019
Q1 		$5K Hold
200
– – 0.1% 100
2018
Q4 		$4K Buy
+200
New +$5.64K ﹤0.01% 261

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Loeb Partners Corp's RIGL Position: Q2 2019 in Review

Loeb Partners Corp sold out of Rigel Pharmaceuticals (RIGL) in Q2 2019, closing a stake of 200 shares — an estimated $5K sold.

Loeb Partners Corp first reported a position in RIGL in Q4 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2019. 127 funds tracked by Wall St. Rank hold RIGL as of Q2 2019.

  • Loeb Partners Corp reported no remaining Rigel Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Loeb Partners Corp sold 200 Rigel Pharmaceuticals shares in Q2 2019, an estimated $5K.
  • Loeb Partners Corp first reported a position in Rigel Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Loeb Partners Corp's Rigel Pharmaceuticals position peaked at $5K in Q1 2019.
  • 127 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2019.

Based on Loeb Partners Corp's 13F filing for Q2 2019.